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Strengths and limitations of this study
 ► This is a UK multicentre study recruiting 320 con-
secutive children and young people in 12 paediatric 
dermatology departments.
 ► The trained investigator undertaking the diagnostic 
criteria assessment is blinded to the participant’s 
reference standard of a dermatologist’s diagnosis.
 ► A case–control study design is likely to overestimate 
the diagnostic accuracy, but this is an appropriate 
and feasible study design for a diagnostic criteria 
development study.
 ► External validation of the diagnostic criteria will be 
needed in the setting and population that the criteria 
will be used.
AbStrACt
Introduction Diagnosing psoriasis in children can be 
challenging. Early and accurate diagnosis is important 
to ensure patients receive psoriasis specific treatment 
and monitoring. It is recognised that the physical, 
psychological, quality of life, financial and comorbid 
burden of psoriasis are significant. The aim of this study 
is to develop clinical examination and history-based 
diagnostic criteria for psoriasis in children to help 
differentiate psoriasis from other scaly inflammatory 
rashes. The criteria tested in this study were developed 
through a consensus study with a group of international 
psoriasis experts (International Psoriasis Council).
Methods and analysis Children and young people (<18 
years) with psoriasis (cases) and other scaly inflammatory 
skin diseases (controls) diagnosed by a dermatologist are 
eligible for recruitment. All participants complete a single 
research visit including a diagnostic criteria assessment by 
a trained investigator blinded to the participant’s diagnosis. 
The reference standard of a dermatologist’s diagnosis 
is extracted from the medical record. Sensitivity and 
specificity of the consensus derived diagnostic criteria will 
be calculated and the best predictive criteria developed 
using multivariate logistic regression.
Ethics and dissemination Health Regulatory Authority 
and National Health Service Research Ethics Committee 
approvals were granted in February 2017 (REC Ref: 17/
EM/0035). Dissemination will be guided by stakeholders; 
patients, children and young people, dermatologists, 
primary care and paediatric rheumatologists. The aim is to 
publish the study results in a high-quality peer-reviewed 
journal, present the findings at international academic 
meetings and disseminate more widely through social 
media and working with patient associations.
trial registration number ISRCTN98851260.
IntroduCtIon
Psoriasis is a chronic immune-mediated 
inflammatory disease of the skin and 
joints.1 2 It is recognised by the World Health 
Organisation (WHO) as a serious non-com-
municable disease and an area of unmet 
health need.3 Although the exact causes for 
the onset of psoriasis are not fully under-
stood, they originate in a complex interaction 
between genetic and environmental factors.4 
Psoriasis can affect the face, hands, nails, 
genitals and flexures, therefore, it is both the 
extent and the location of disease that are 
important to patients. It is known that the 
physical, psychological, quality of life, finan-
cial and comorbid burden of psoriasis are 
significant.5–11
Psoriasis can affect people of all ages. 
However, making the diagnosis in children 
and young people can be more challenging 
compared with diagnosing psoriasis in adults. 
Psoriasis is often under-recognised in this 
younger age group and may be misdiagnosed 
as other common red scaly rashes such as 
eczema, viral exanthems and fungal infec-
tions. The clinical features seen in childhood 
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box 1 Sixteen diagnostic features agreed by the 
International Psoriasis Council to be important for 
the diagnosis of plaque psoriasis in children (26). 
two additional diagnostic features (*) have also been 
included that were close to reaching consensus and were 
emphasised as important in the feedback from experts.
Major criteria
 ► Scaly erythematous plaques on the extensor surfaces of the elbows 
and knees.
 ► Scaly erythematous plaques on the trunk triggered by a sore throat 
or other infection.
 ► Raindrop plaques typical of guttate disease on the trunk or limbs.
Minor criteria
 ► Scale and erythema in the scalp involving the hairline.
 ► Retroauricular erythema (including behind the earlobes).
 ► Scaly erythema inside the external auditory meatus.
 ► Persistent well-demarcated erythematous scaly rash anywhere on 
the body.
 ► Fine scaly patches involving the upper thighs and buttocks.
 ► Well-demarcated erythematous rash in the napkin area involving 
the crural folds.
 ► Persistent erythema in the umbilicus.
 ► Nail pitting.
 ► Onycholysis of the nail(s).
 ► Subungual hyperkeratosis of the nail(s).
 ► Positive family history of psoriasis.
 ► Koebner phenomenon.
 ► Fusiform swelling of a toe or a finger suggestive of dactylitis.
*Persistent well-demarcated facial rash with fine or absent scale.
*Natal cleft erythema and/or skin splitting.
disease are often more subtle with thinner plaques, facial 
involvement and flexural disease in hidden sites normally 
covered by clothing.12–14 Therefore, the diagnosis of 
psoriasis in children and young people may be missed by 
non-dermatologists.
Epidemiological data are limited, but it is estimated 
that one-third of adults with psoriasis first develop skin 
changes in childhood.15 16 Therefore, early and accurate 
diagnosis presents an opportunity for early interven-
tion. National Institute for Health and Care Excellence 
(NICE) recommends all children with suspected psoriasis 
are referred to a dermatology specialist for assessment 
and management.17 This specialist review also includes 
initiating monitoring for comorbid diseases and assess-
ment for juvenile psoriatic arthritis. Accurate recognition 
of psoriasis is also important to help paediatric rheuma-
tologists differentiate juvenile idiopathic arthritis into 
juvenile psoriatic arthritis. This differentiation alters the 
treatment pathway and likely prognosis for children with 
juvenile psoriatic arthritis.18 Ensuring children and young 
people receive psoriasis specific treatment and moni-
toring from the onset is important to help minimise the 
negative long-term consequences of psoriasis, known as 
cumulative life course impairment.19
There are no clinical examination-based diagnostic 
criteria for psoriasis.20 Diagnosis in clinical practice 
currently relies on expert pattern recognition by a 
trained dermatologist.21 22 Skin biopsies are not routinely 
taken, especially in children. Consequently, there are no 
available diagnostic aids to support non-dermatologists to 
recognise psoriasis in children. In research studies, the 
case-definition and eligibility criteria for psoriasis in chil-
dren are often poorly described, reducing the generalis-
ability and ability to synthesis studies.23 24
Improving awareness of psoriasis has been identified 
as a topic of importance in the Psoriasis and Psoriatic 
Arthritis Alliance (PAPAA) prioritisation exercise. The 
recently completed James Lind Alliance Psoriasis Priority 
Setting Partnership (PSP) identified 10 research priori-
ties in psoriasis that are important to people who have 
psoriasis, their families and friends, and the healthcare 
professionals who treat them. The second priority asks 
‘Does treating psoriasis early (or proactively) reduce 
the severity of the disease, make it more likely to go into 
remission, or stop other health conditions developing’.25 
In children and young people, ensuring early and accu-
rate recognition of psoriasis will be a necessary part of 
answering this question.
An initial eDelphi consensus study has been completed 
with a group of global clinically active psoriasis experts 
who are members of the International Psoriasis Council. 
The group agreed 16 clinical features that are important 
for the diagnosis of plaque psoriasis in children.26
The next step in developing diagnostic criteria for psori-
asis in children is to empirically test how well the consen-
sus-derived diagnostic criteria perform and to refine the 
criteria. The Developing DIagnostic criteria for PSOri-
asis in Children (DIPSOC) study has been designed to 
develop a diagnostic tool for identifying childhood psori-
asis. The primary objective is to test the diagnostic accu-
racy (sensitivity and specificity) of the consensus agreed 
diagnostic criteria (box 1) and develop the best predictive 
diagnostic criteria using multivariate analysis. DIPSOC is 
a development study because further validation work is 
needed before the diagnostic accuracy of the criteria in 
primary, secondary and research settings are known.
MEthodS
Study design
DIPSOC is a multicentre case–control diagnostic accu-
racy study with a nested substudy. The nested substudy is 
recruiting children and young people with indeterminate 
psoriasis alongside the main study. The full protocol was 
lodged on the Centre of Evidence Based Dermatology 
website prior to the first participant being recruited. 
This published protocol is based on Protocol 12.10.2017 
Final V.1.2. The full protocol is available on the Centre of 
Evidence Based Dermatology University of Nottingham 
website www. nottingham. ac. uk/ go/ dipsoc.
Primary objective
To test the diagnostic accuracy of the consensus agreed 
diagnostic criteria for plaque psoriasis in children/young 
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Figure 1 Developing DIagnostic criteria for PSOriasis in 
children study flow. CRN, Clinical Research Network.
people and develop the best predictive diagnostic criteria 
using multivariate analysis.
Secondary objectives
1. To compare the diagnostic performance of the con-
sensus agreed diagnostic criteria and the best predic-
tive criteria for plaque psoriasis in children and young 
people.
2. To assess the interobserver variability in the diagnostic 
criteria assessment.
3. To assess the variability in the reference standard for 
psoriasis.
Setting
DIPSOC is recruiting in 12 UK paediatric dermatology 
outpatient clinics in secondary and tertiary care. This 
setting is a feasible environment in which the reference 
standard (dermatologist’s diagnosis) can be obtained and 
the sample size recruited within the time and resources 
available. A specialist setting is appropriate for a develop-
ment study, but validation research will be needed to test 
the performance of the diagnostic criteria in the settings 
that they are intended to be used (eg, primary care and 
paediatric rheumatology clinics).
Participant selection
Inclusion criteria
Cases and controls are children and young people aged 
0 to <18 years, with active skin disease (rash present) at 
the time of assessment and are able to consent or have a 
parent/guardian willing to give consent.
Cases have a confirmed diagnosis of plaque psoriasis by 
a dermatologist. Plaque psoriasis has been used as a broad 
term to include all subtypes and presentations of psoriasis 
where plaques are the main feature. For example, chronic 
plaque psoriasis, guttate psoriasis, scalp psoriasis and flex-
ural psoriasis are included but purely nail psoriasis or 
juvenile psoriatic arthritis without skin involvement are 
excluded. The decision to include guttate psoriasis under 
the broad description of plaque psoriasis was agreed with 
the International Psoriasis Council.
Controls have a confirmed diagnosis of a scaly inflamma-
tory rash (excluding psoriasis or indeterminate psoriasis) 
by a dermatologist. Skin conditions that may be included 
in the control population are eczema (atopic dermatitis), 
pityriasis rubra pilaris, pityriasis rosea, ichthyosis, mycosis 
fungoides, Gianotti-Crosti and tinea corporis. These 
conditions are not an exhaustive list and the decision as 
to whether a participant’s skin disease meets the eligibility 
criteria is made by the patient’s dermatologist.
Exclusion criteria
Children or young people with pustular psoriasis, 
erythrodermic psoriasis or do not have a dermatologist’s 
diagnosis.
Index test
A diagnostic criteria assessment looking for the presence 
or absence of each of the diagnostic features (box 1). 
Using the same assessment, the index test is divided into 
index test 1 and index test 2.
Index test 1
The international eDelphi consensus study agreed 16 
diagnostic features of childhood psoriasis and separated 
them into major and minor criteria. In the consensus 
study, a scoring algorithm was proposed where the pres-
ence of one or more major criteria or three of more minor 
criteria would support a diagnosis of psoriasis. Together 
these 16 diagnostic features and the scoring algorithm 
form index test 1.26
Index test 2
Two additional features were close to reaching consensus 
and were emphasised as important in the feedback from 
the expert participants. These 18 items will be used to 
create the best predictive criteria using multivariate anal-
ysis. The best predictive criteria form index test 2.
reference test
A dermatologist’s diagnosis as recorded in the partic-
ipant’s medical record. The diagnosis is a clinical diag-
nosis and may include, but does not require, a skin biopsy.
Study flow
The study flow is depicted in figure 1. Children and young 
people who meet the eligibility criteria to be a case or 
control are approached by their usual dermatology team. 
They are invited to attend a research visit on the same day, 
at their next consultation or at a separate research visit. 
All consecutive psoriasis patients are being approached 
and consecutive control patients when a case is identi-
fied. Cases identified from existing medical records are 
approached by letter from their usual dermatology team.
After informed consent has been taken, all participants 
undergo the same research visit. The visit comprises demo-
graphic questions, quality of life questionnaires (for those 
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box 2 A summary of the data variables collected in the 
dIPSoC study
research visit
 ► Demographic information: age, sex, ethnicity, household occupation.
 ► Diagnostic criteria assessment: presence and absence of each of 
the 18 diagnostic features (index test).
 ► Clinical experience of the diagnostic criteria assessor.
 ► Unblinding of the diagnostic criteria assessor.
 ► Quality of life questionnaires (4–17 years)—CDLQI and CHU-9D.
 ► Contact details (optional consent).
Medical record
 ► Participant’s diagnosis (reference standard).
 ► Age at diagnosis.
 ► Age at onset of symptoms.
 ► Skin biopsy result.
 ► Disease severity.
 ► Presence of psoriatic arthritis.
 ► Current skin treatments—topical, systemic, phototherapy.
 ► Clinical photographs (optional consent).
CDLQI, Children’s Dermatology Life Quality Index; CHU-9D, Child Health Utility 
9D; DIPSOC, Developing DIagnostic criteria for PSOriasis in Children.
aged 4–17 years) and a diagnostic criteria assessment by 
a study investigator who is blinded to the participant’s 
diagnosis (blinded to the reference standard). The two 
quality of life questionnaires are the Children’s Derma-
tology Life Quality Index and the Child Health Utility 9D.
Each participant is offered a certificate, sticker and 
voucher to say thank you for taking part. Following the 
research visit, information is extracted from the medical 
record by an investigator who did not perform the assess-
ment (blinded to the index test). Data to be extracted 
include the reference standard (diagnosis of skin 
disease), duration of disease, disease severity and current 
treatments. A summary of the data variables collected in 
the DIPSOC study is presented in box 2.
data management
Data are collected at the time of assessment and from 
the medical record. A number of steps have been taken 
to help ensure high-quality data collection. All DIPSOC 
study investigators undergo standardised training and 
receive a study manual to use as a practical guide when 
conducting the study. All DIPSOC diagnostic criteria 
assessors are trained using a PowerPoint presentation by 
EB-T (a clinical dermatologist with an interest in paedi-
atric psoriasis) either face to face or by teleconference. 
Diagnostic criteria assessors come from both a derma-
tology and non-dermatology background. Understanding 
of the training material is checked using a short assess-
ment based on clinical photographs. All assessors are 
required to achieve a minimum of 90% in the assessment 
prior to starting the study. The diagnostic criteria training 
manual is provided as a reference aid for investigators to 
use during their assessment.
The case report form includes guidance notes and was 
piloted to check for accuracy of completion. Quality of life 
is measured using validated measurement instruments. A 
data management process has been designed to minimise 
errors. All data monitoring is taking place centrally and 
data queries are checked with individual recruiting sites. 
Data checks are also built into the database design and all 
data for the primary objective will be entered twice.
Consistency checks
To assess the interobserver variability in the diagnostic 
criteria assessment, the assessment will be conducted 
consecutively by two independent assessors in the first 
forty participants where two assessors are available.
To assess the variability in the reference standard for 
psoriasis, when optional consent is given, anonymised 
clinical photographs of cases taken as part of routine 
clinical care will be sent as anonymised case studies to 
the twelve consultant dermatologist principal investi-
gators. The consultant dermatologists will be asked to 
score whether they agree or disagree with the diagnosis 
of psoriasis.
Sample size and data analysis
The sample size is based on the primary objective. First, 
based on a 95% CI that the positive likelihood ratio (LR) 
is greater than 2 assuming a ratio of 1:1 cases to controls 
and an estimated sensitivity of 0.8 and specificity of 0.7 
the sample size required is 74 cases and 74 controls.27
Second, transparent reporting of multivariable 
prediction models for individual prognosis or diagnosis 
(TRIPOD) has stated that there are no clear methods 
for calculating an adequate sample size. The guidance 
supports the current rule of thumb for sample size 
calculations of 10 events per variable.28 As there are 16 
diagnostic features in the consensus agreed diagnostic 
criteria, a sample size of 160 cases and 160 controls has 
been calculated.
Participant characteristics will be analysed using 
descriptive statistics. The diagnostic accuracy of the 
consensus agreed criteria will be calculated using sensi-
tivity and specificity; 95% CIs will be presented. Multi-
variate logistic regression analysis will be used to develop 
the best predictive criteria using the DIPSOC data. The 
diagnostic features will be entered into the backward 
regression model. All minor criteria will be entered into 
the regression model and LR will be presented. Variation 
of diagnostic accuracy in different clinical contexts will 
be explored in stratified analysis for the following vari-
ables; age at the time of assessment, sex, assessor type and 
consultation type (new or follow-up).
The results of the multivariate analysis will be plotted on 
a receiver operator characteristic (ROC) curve and a coef-
ficient threshold determined. The minimum threshold 
for the best predictive criteria has been set at 0.8 sensi-
tivity and 0.8 specificity after consultation with the expert 
advisory group (detailed in the acknowledgements). The 
best predictive diagnostic criteria will be applied to the 
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box 3 Suggestions from patient and public involvement 
work that have informed the dIPSoC study
Study design.
 ► Include on the day recruitment and the option to attend for a sepa-
rate research visit.
 ► Invite participants by letter in advance of their clinic appointment.
Participant information sheets
 ► Change the format to a leaflet or booklet.
 ► Colourful boxes around the text and different colours for different 
sections.
 ► Emphasise confidentiality and the assessment will take place in a 
private space.
 ► Include photographs of the research team.
 ► Do not include photographs of psoriasis.
 ► Provide electronic versions of the information sheets on a website.
Create a distinctive logo for the study
Provide a colouring-in sheet.
Give a certificate and sticker at the end of the research visit.
study data and sensitivity and specificity calculated. The 
performance of the consensus agreed criteria and the 
best predictive model criteria will be compared using area 
under the ROC curve.
Interobserver variability and variability in the refer-
ence standard will be calculated using the kappa statistic. 
Further details on the analysis will be made public in 
the statistical analysis plan which will be shared on the 
DIPSOC website www. nottingham. ac. uk/ go/ dipsoc 
before the end of recruitment.
Minimising bias
We have minimised selection bias by asking sites to 
approach all eligible cases and consecutive controls. All 
those approached but not recruited will be included in a 
screening log to demonstrate a non-selective approach. 
By minimising exclusion criteria, we aimed to design an 
inclusive study to support generalisation of the results.
The diagnostic criteria assessment will be undertaken 
by an investigator who is unaware of (blinded to) the 
dermatologist’s diagnosis of the participant. Investigators 
are trained to focus on the presence or absence of each 
clinical feature. The study will test a prespecified scoring 
algorithm proposed through the eDelphi consensus study 
and a prespecified diagnostic threshold decided with the 
expert advisory group.
Bias in the reference standard will be minimised by 
ensuring all participants have a confirmed diagnosis by 
a dermatologist. As this is a case–control study, the refer-
ence standard will predate the index test. Variability in 
the reference standard will be examined using clinical 
photographs.
We have designed the study to include same day recruit-
ment directly from clinic, therefore, the time between the 
reference standard and index test for most participants 
will be short. All participants receive the same refer-
ence standard (a dermatologist’s diagnosis), therefore, 
complete verification will be achieved. All participants 
will be included within the analysis and a complete data 
set sensitivity analysis is planned. Data are extracted from 
the medical record by an investigator who did not under-
take the diagnostic criteria assessment (blinded to the 
index test).
Patient and public involvement
The patient and public involvement aim in this study 
was to inform our understanding of the importance of 
diagnosis to patients, to make sure the study design was 
patient centred, to ensure the participant facing docu-
ments were what patients wanted and to inform dissem-
ination. A patient advisor (CH) has been involved from 
the beginning of the project and is a study coauthor. 
PAPAA, a UK patient association, is a supporting organ-
isation. We have also met the Young Person’s Advisory 
Group (YPAG) for Research Nottingham and patients 
in paediatric dermatology clinics.
The research questions were developed and informed 
by the patient association prioritisation work, discussion 
with our patient advisor and the YPAG. We discussed 
what diagnosis means to young people and the impor-
tance of being able to give a name to a disease. Important 
suggestions from these groups that have informed the 
study are presented in box 3. The above groups will 
guide dissemination to patient communities.
Substudy
The objective of the substudy is to assess the perfor-
mance of the best predictive diagnostic criteria to 
identify psoriasis in children/young people currently 
diagnosed with indeterminate disease. Children and 
young people with possible or indeterminate psoriasis 
will be recruited alongside the main study to the nested 
substudy. The eligibility criteria and research visit 
are otherwise identical to the main study. No control 
participant is required. Children/young people in the 
substudy will, if consent is provided, be sent a ques-
tionnaire 2 years after the last participant is recruited. 
The questionnaire will ask about their skin disease and 
whether the diagnosis has changed. The substudy data 
will be used to calculate the sensitivity and specificity of 
the best predictive criteria in identifying children and 
young people previously diagnosed with indeterminate 
psoriasis who go on to be diagnosed with psoriasis.
EthICS And dISSEMInAtIon
Ethics
The four principles of biomedical ethics were consid-
ered in the study design and documentation. The 
purpose, aims and details of taking part in the study 
are explained in the participant information sheets. It 
is explained that taking part is voluntary and not taking 
part will have no effect on the patient’s medical care. 
Informed consent is necessary before any part of the 
study is completed. It is also explained that taking part 
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in the study will have no direct medical benefit for the 
patient, but may help the diagnosis of other children or 
young people in the future. The study is non-interven-
tional and non-therapeutic. All study investigators are 
required to be Good Clinical Practice trained.
dissemination
Dissemination will be guided by stakeholders; patients, 
children and young people, dermatologists, primary 
care and paediatric rheumatologists. The aim is to 
publish the study results in a high-quality peer-reviewed 
journal and present the findings at international 
academic meetings. The results will also be shared 
through social media and the supporting patient asso-
ciation (PAPAA).
dISCuSSIon
DIPSOC is a development study and the first in a series 
of studies needed to develop, test and validate the diag-
nostic accuracy of criteria for psoriasis in children/young 
people. The nested substudy will be important to inves-
tigate whether the criteria can help identify children 
with psoriasis at an indeterminate stage, before their skin 
disease may have fully evolved.
The development and introduction of diagnostic 
criteria for psoriasis in children/young people has the 
potential to improve the early and accurate recognition of 
psoriasis and juvenile psoriatic arthritis, prompt referral 
for specialist assessment and monitoring, standardise clin-
ical research to enable meta-analysis of data and support 
case finding in new epidemiological studies. The utility 
of diagnostic criteria will, therefore, be in primary and 
secondary care as well as clinical research.
Limitations
DIPSOC has been designed to ensure a high-quality diag-
nostic study, but there are some important limitations. 
A case–control study design is likely to overestimate the 
diagnostic accuracy of the criteria. DIPSOC is a develop-
ment study, and therefore, this study design is appropriate 
and feasible for this early stage of testing. In the future, 
further diagnostic cohort studies are needed to test, 
potentially improve, and validate the resulting criteria in 
the setting and population they are intended to be used. 
Another limitation of the study design is spectrum bias. 
Participants recruited from paediatric dermatology clinics 
are likely to have more severe and persistent disease (ie, 
a different clinical presentation) compared with chil-
dren/young people in the community who are managed 
by general practitioners. This spectrum bias may lead 
to an overestimation of the diagnostic accuracy because 
participants may have more obvious disease. DIPSOC 
recruits both new and follow-up (incident and prevalent) 
patients. This will include participants currently on treat-
ment who’s skin rashes may have changed since starting 
treatment. However, paediatric dermatology clinics are a 
feasible setting to recruit the required sample size and 
obtain a reference standard to ensure complete verifi-
cation. DIPSOC does not include external validation of 
the best predictive criteria and this will need to be under-
taken in separate studies once the diagnostic criteria have 
been developed.
Study progress
Twelve UK centres are open for recruitment. These 
centres are Nottingham, Barts London, Middlesbrough, 
Cambridge, Sheffield, Coventry, Glasgow, Dorchester, 
Oxford, St George’s London, Plymouth and Cardiff. The 
first participant was recruited in October 2017 and the 
study is due to finish recruiting on August 2019. We are 
currently in the data collection phase.
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